Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H20F3N3O4.ClH |
| Molecular Weight | 447.836 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.C[C@H]1CN(CCN1)C2=C(OC(F)F)C3=C(C=C2F)C(=O)C(=CN3C4CC4)C(O)=O
InChI
InChIKey=AWPMTCKEQGUMTG-FVGYRXGTSA-N
InChI=1S/C19H20F3N3O4.ClH/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28;/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28);1H/t9-;/m0./s1
DescriptionCurator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8723467
Curator's Comment: Description was created based on several sources, including http://www.ncbi.nlm.nih.gov/pubmed/8723467
Cadrofloxacin hydrochloride was studied for the treatment of bacterial infections. The compound was originally developed by UBE and Daiichi Sankyo. However, this study was discontinued. The compound currently was developed by Hengrui. Cadrofloxacin showed potent bactericidal activity against S. aureus, Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Staphylococcus aureus growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375 |
|||
Target ID: Streptococcus pneumoniae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375 |
|||
Target ID: Haemophilus influenzae growth Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [In vitro anti-MAC activities of new quinolones in focus (1)]. | 1996-09 |
|
| [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media]. | 1996-08 |
|
| Antimicrobial activity of CS-940, a new trifluorinated quinolone. | 1995-10 |
Patents
Sample Use Guides
400 mg cadrofloxacin hydrochloride once a day for 7 d by intravenous drip infusion
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/9371375
Cadrofloxacin (CS-940) was active against methicillin-resistant S. aureus with MIC90 of 16 ug/ml.
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
128427-55-4
Created by
admin on Mon Mar 31 21:33:28 GMT 2025 , Edited by admin on Mon Mar 31 21:33:28 GMT 2025
|
PRIMARY | |||
|
9889840
Created by
admin on Mon Mar 31 21:33:28 GMT 2025 , Edited by admin on Mon Mar 31 21:33:28 GMT 2025
|
PRIMARY | |||
|
2XR10ID7XQ
Created by
admin on Mon Mar 31 21:33:28 GMT 2025 , Edited by admin on Mon Mar 31 21:33:28 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD